Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds.
The offering comprises 5.54 million shares of common stock priced at $23.50 per share.
In addition, the company is offering pre-funded warrants to purchase up to 850,000 shares at a price of $23.499 per warrant.
The offering is expected to close on or about April 23.
The company stated that proceeds will be used primarily to advance research and development of its product candidates, including MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, as well as for general corporate purposes.
The company expects the net proceeds, combined with existing cash and marketable securities, to fund operations into 2029.
On Tuesday, Maze Therapeutics closed trading 4.28% lesser at $25.69 on the Nasdaq. In the after-hours trading, 1.01% higher at $25.95 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.